Cilostazol (Pletal) For Intermittent Claudication

• INN (International Nonproprietary Name): Cilostazol
• Brand Names Available In United Kingdom: Pletal — Tablets 100 mg, 56 tab
• ATC Code: B01AC23
• Forms & Dosages: Tablet 100 mg (round) commonly supplied in 20, 30 or 56 tablet packs; 50 mg triangular tablets exist in some Asian markets but are rare.
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: MHRA‑licensed and available via standard prescription (Rx).
• OTC / Rx Classification: Prescription Only Medicine (Rx)

Major 2022–2025 Studies

Which trials should clinicians and patients know about when considering cilostazol for claudication?

Recent randomised trials and large observational analyses between 2022 and 2025 reconfirmed cilostazol as an option for intermittent claudication, showing benefit over placebo or pentoxifylline in many cohorts.

Several studies reported that combining cilostazol with supervised exercise produced larger gains in walking distance than drug or exercise alone.

Real‑world NHS analyses included in the 2022–2025 literature showed effect sizes similar to trial data when applied to routine vascular clinic populations.

Main Outcomes

What improvements were consistently observed in the evidence?

Most trials documented modest to moderate increases in pain‑free and maximal walking distance that typically became apparent between four and twelve weeks of therapy.

Magnitude of benefit varied with endpoint definition, with some studies favouring improvements in maximal walking distance while others focused on pain‑free distance.

Health‑economic models that accounted for limited access to supervised exercise suggested cilostazol can be cost‑effective in targeted patients with symptomatic peripheral arterial disease.

Safety Observations

Were there recurring safety themes across these recent publications?

Adverse‑event patterns were reproducible and dominated by headache, diarrhoea and palpitations or tachycardia, which were generally mild to moderate and often transient.

Regulatory and trial reports restated the class signal for worse outcomes in heart‑failure patients, confirming absolute contraindication in any degree of heart failure.

Under‑representation of frail older adults was a persistent limitation, so clinicians should adopt a cautious approach in very elderly or multimorbid patients.

Layman’s Explanation

How does cilostazol help people with leg pain from peripheral arterial disease?

Cilostazol helps by making small blood vessels relax and by reducing the tendency of platelets to clump together, which improves blood flow to leg muscles and usually lets people walk further before pain starts.

Patients often notice changes in walking capacity within a few weeks but full benefit may take up to three months.

Scientific Breakdown

What is the pharmacology behind cilostazol?

Cilostazol is a phosphodiesterase‑III (PDE3) inhibitor with two principal effects: antiplatelet activity and vasodilation via raised intracellular cyclic AMP.

This dual mechanism reduces platelet aggregation and relaxes vascular smooth muscle, which together improve perfusion of ischaemic muscle during exercise.

Pharmacodynamics

PDE3 inhibition increases cyclic AMP in platelets and vascular smooth muscle, producing reduced thrombosis tendency and vasodilation.

These actions translate clinically into improvements in walking distance for many patients with intermittent claudication.

Pharmacokinetics And Metabolism

Cilostazol is administered orally with a typical adult dose of 100 mg twice daily taken around meals to optimise absorption.

The drug is metabolised hepatically with CYP3A4 and CYP2C19 involved, making interactions with strong inhibitors clinically important.

Class Safety Note

PDE3 inhibitors have been associated with worsening heart failure, and cilostazol carries an absolute contraindication in any degree of heart failure consistent with MHRA and other national labelling.

Prescribers should consult MHRA and NICE references when translating mechanism into practice for UK patients.

United Kingdom Approvals

Is cilostazol licensed for use in the UK?

Cilostazol (brand Pletal) is licensed in the United Kingdom for the treatment of intermittent claudication secondary to peripheral arterial disease and is available as a prescription medicine.

Local NHS formularies often permit specialist‑initiated or secondary‑care initiation with primary‑care continuation depending on local vascular pathways.

Notable Off‑Label Trends

Do clinicians use cilostazol for anything beyond its licence?

Some clinicians consider cilostazol in off‑label contexts such as microvascular ischaemia, as an adjunct to wound healing in PAD clinics, or in small pilot trials for vascular cognitive or neuropathic symptoms.

These uses are driven by mechanistic rationale or small studies and lack robust licensing support, so shared decision‑making and documentation are essential in the UK setting.

General Dosing

What is the standard dosing strategy for adults?

The standard adult dose is 100 mg orally twice daily, taken about 30 minutes before meals or at least two hours after meals to optimise absorption.

Patients typically need at least two to four weeks to show early improvement and up to twelve weeks for the full effect; stop if there is no meaningful benefit by about three months.

Condition‑Specific Dosing

How should dosing be adjusted for special patient groups?

Elderly patients require cautious initiation but routine dose reduction is not universally recommended; monitor for tachycardia, dizziness and orthostatic symptoms.

Renal impairment does not automatically require dose reduction but clinical judgment is needed, particularly in severe renal disease where adverse events may increase.

Moderate to severe hepatic impairment is a contraindication and cilostazol should be avoided in severe liver disease.

Paediatric use is not recommended as safety and efficacy are not established.

Contraindications

Who must never receive cilostazol?

Any patient with heart failure of any degree (NYHA I–IV) must not receive cilostazol because of class‑related mortality signals with PDE3 inhibitors.

Other absolute contraindications include known hypersensitivity to cilostazol or excipients and severe hepatic impairment.

Adverse Effects

What side effects should patients expect and how should clinicians monitor them?

Common side effects include headache, diarrhoea, abnormal stools, palpitations or tachycardia, dizziness and peripheral oedema, most of which are mild and often resolve with continued therapy.

Serious events such as arrhythmias or hypotension are less frequent and should prompt immediate review and discontinuation if suspected.

Baseline cardiovascular assessment and early pulse and blood pressure checks after initiation are sensible monitoring steps in primary care.

Food Interactions

Are there dietary rules when taking cilostazol?

Food affects absorption, so advise patients to take cilostazol 30 minutes before or two hours after meals to reduce variability in blood levels and optimise efficacy.

Alcohol is not specifically contraindicated but caution is sensible because combined vasodilatory effects may increase dizziness or hypotension.

Drug Combinations To Avoid

Which medicines interact with cilostazol?

Cilostazol is metabolised by CYP3A4 and CYP2C19, so strong inhibitors of these enzymes (for example some azole antifungals and protease inhibitors) can raise cilostazol concentrations and increase adverse effects.

Concurrent use of other antiplatelets or anticoagulants raises bleeding risk and requires a careful risk–benefit assessment and monitoring plan.

Check the BNF and MHRA interaction tables before combining cilostazol with SSRIs, potent CYP inhibitors or other cardiovascular drugs.

Survey Data

How do patients report their experience in real clinics and registries?

Patient‑reported outcome measures generally show improved walking distance and modest quality‑of‑life gains, especially when cilostazol is used alongside supervised exercise therapy.

Adherence correlates with symptom relief; common causes for stopping are headache, palpitations and perceived lack of benefit by three months.

Forum Trends

What do online forums say about taking pletal?

Patient forums commonly show two narratives: people who report meaningful walking improvement and those who discontinue due to palpitations or persistent headaches.

Clear patient counselling about the 2–12 week timeline and side‑effect expectations helps align real‑world experience with clinical trial outcomes.

Manufacturing And Supply

Who supplies cilostazol and how stable is availability?

Original manufacturer Otsuka and several generics such as Zentiva, Actavis and Krka supply cilostazol globally, and Pletal 100 mg tablets are listed in UK pharmacies as 56‑tablet packs.

Brand availability can vary internationally, with generics commonly used where Pletal brand supplies are limited.

Pricing And Procurement

How does cost influence prescribing decisions in the UK?

Generics generally reduce acquisition cost compared with the original brand and local NHS tariff and procurement arrangements determine the actual cost to the health service.

Economic models indicate improved cost‑effectiveness when cilostazol is used where supervised exercise is unavailable or limited.

In our online pharmacy, pletal is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparison Table

Which alternatives should prescribers consider for intermittent claudication?

Pentoxifylline offers modest symptomatic benefit and fewer cardiac contraindications but is often less effective than cilostazol for walking distance.

Naftidrofuryl is an alternative used in parts of Europe with mixed evidence and limited UK availability.

Supervised exercise therapy remains the first‑line non‑drug intervention with the strongest guideline support.

Pros And Cons

Cilostazol: pro — superior walking distance improvement in many trials; con — absolute contraindication in heart failure and common side effects such as headache and palpitations.

Pentoxifylline: pro — better tolerability in some patients; con — typically smaller gains in walking distance.

Naftidrofuryl: pro — alternative where available; con — heterogeneous evidence and limited access in the UK.

Regulatory Status

What do national regulators say about cilostazol?

Cilostazol is approved internationally for intermittent claudication and remains a prescription‑only medicine across major jurisdictions, with MHRA licensing in the UK.

Regulatory labelling includes the absolute heart‑failure contraindication and warnings about hepatic impairment and CYP interactions.

Report suspected serious adverse reactions to the Yellow Card scheme to support ongoing pharmacovigilance.

Consolidated FAQ

What quick answers do patients and prescribers regularly ask?

• What is Pletal? — Pletal is the brand name for cilostazol, a PDE3 inhibitor indicated for intermittent claudication.
• How is it dosed? — Standard adult dosing is 100 mg twice daily, around meals.
• Who must not take it? — Anyone with heart failure, severe hepatic impairment, or known hypersensitivity.
• When to expect benefit? — Early improvements in 2–4 weeks; full effect up to 12 weeks; stop if no benefit by about three months.
• Side effects to watch for? — Headache, diarrhoea, palpitations, dizziness and peripheral oedema; seek urgent review for chest pain or severe palpitations.
• Interactions? — Strong CYP3A4/CYP2C19 inhibitors increase levels; anticoagulants/antiplatelets raise bleeding risk.
• Availability in UK? — Prescription only; Pletal 100 mg tablets commonly supplied as 56‑tablet packs.

Tablet Identification

How can patients and pharmacists recognise Pletal tablets?

Pletal is commonly presented as round 100 mg tablets in blister packs or boxes in European markets, and 50 mg triangular tablets are very rare and typically limited to Asian markets.

Packaging and labelling show INN cilostazol and ATC code B01AC23 on authorised products.

Pharmacology Infographic Notes

What should a clinical infographic highlight for patient leaflets or waiting‑room displays?

Key points include dual PDE3 antiplatelet and vasodilator action, expected clinical timeline (2–4 weeks initial, up to 12 weeks full), absolute contraindication for heart failure, and common side effects such as headache and palpitations.

Include a simple flowchart for UK prescribers: confirm PAD diagnosis → start or confirm supervised exercise → consider cilostazol if insufficient → prescribe 100 mg twice daily with monitoring → reassess at 8–12 weeks.

Storage & Transport

How should pharmacies and patients store and transport cilostazol?

Store at room temperature, typically 15–30°C, in a dry place and keep blister packs protected from light.

Short‑term transport at ambient conditions is acceptable, but avoid extreme heat, humidity or freezing during courier transit.

Dispense in original blister where possible and advise patients to return unused medicines to the pharmacy for safe disposal.

Prescribing Checklist

What practical steps should UK prescribers follow before issuing a prescription?

Confirm intermittent claudication diagnosis and PAD assessment, ensure supervised exercise has been tried or is inappropriate, screen for heart failure and severe hepatic impairment, review medicines for CYP3A4/CYP2C19 inhibitors and anticoagulants, and document expected timeline and side effects.

Follow‑Up And Discontinuation Criteria

When should therapy be reviewed or stopped?

Arrange an early tolerability check at four to eight weeks and a formal functional reassessment at eight to twelve weeks using baseline walking distance or patient‑centred targets.

Stop treatment if there is no meaningful improvement after about three months, if severe intolerance develops, or if the patient is newly diagnosed with heart failure.

Patient Counselling Notes

How should clinicians set expectations for patients starting pletal?

Explain that benefits often start within a few weeks but may require up to three months, and that common side effects such as headache or palpitations often settle.

Advise the dosing window (30 minutes before or two hours after food) and to report chest pain, breathlessness or fast palpitations immediately.

Alternatives And Pathway Summary

What is the recommended treatment pathway in the UK?

Emphasise supervised exercise therapy as first‑line care, consider cilostazol for patients with documented PAD who do not achieve adequate function with exercise or where exercise is not feasible, and reserve revascularisation for anatomical indications or critical limb ischaemia.

Delivery Across United Kingdom

Final Practical Notes For UK Prescribers

Which simple rules will make prescribing safer and more effective?

Record baseline walking distance or a patient‑centred functional target before starting therapy so that benefit is measurable at follow‑up.

Screen for heart failure and hepatic impairment and avoid cilostazol in those groups as per MHRA labelling.

Discuss the likely side‑effect profile openly, set expectations for a 2–12 week benefit window and plan an 8–12 week formal review to decide whether to continue.

Report any serious suspected reactions to the Yellow Card scheme to support national safety monitoring.